National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 2) - PB 12 of 2014

Link to law: https://www.comlaw.gov.au/Details/F2014L00191

 
PB 12 of 2014
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 2)
 
National Health Act 1953
___________________________________________________________________________
 
I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
 
Dated 23 February 2014
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Principal Pharmacy Advisor
Pharmaceutical Benefits Division
Department of Health
 
___________________________________________________________________
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.2).
 
(2)                This Instrument may also be cited as PB 12 of 2014.
2             Commencement
                This Instrument commences on 1 March 2014.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]     Schedule 1 Part 1, entry for Carboplatin in the form ‘Solution for I.V. injection 150 mg in 15 mL’ with manner of administration Injection:
omit:      
Pfizer Australia Pty Ltd
PF
MP
 
D
 
[2]     Schedule 1 Part 1, entry for Cisplatin in the forms ‘I.V. injection 100 mg in 100 mL’ and ‘I.V. injection 50 mg in 50 mL’ with manner of administration Injection:
omit:      
Pfizer Australia Pty Ltd
PF
MP
 
D
 
[3]     Schedule 1 Part 1, entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/Intravesical:
omit:
Epirubicin Kabi
PK
MP
 
D
 
[4]     Schedule 1 Part 1, entry for Fludarabine in the form ‘Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL’ with manner of administration Injection:
omit:
 
Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL
Injection
AS‑Fludarabine
YA
MP
C3887
PB

 
 
insert:
 
 
Fludarabine Ebewe
SZ
MP
C3887
PB

Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL
 
Injection
Fludarabine-Ebewe
SZ
MP
C3887
PB

[5]     Schedule 1 Part 1, entry for Gemcitabine in the forms ‘Powder for I.V. infusion 2 g (as hydrochloride)’ and ‘Powder for I.V. infusion 200 mg (as hydrochloride)’  with manner of administration Injection:
omit:      
Gemcitabine Kabi
PK
MP
 
D
 
[6]     Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL’ with the manner of administration Injection :
omit:
 
Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL
Injection
Gemcitabine AS
YA
MP
 
D

 
 
Gemcitabine Ebewe
 
SZ
MP
 
D
 

insert:
 
Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL
Injection
Gemcitabine Ebewe
 
SZ
MP
 
D
 
 
[7]     Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL’ with the manner of administration Injection :
omit:
 
Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL
Injection
Gemcitabine AS
YA
MP
 
D

 
 
Gemcitabine Ebewe
 
SZ
MP
 
D
 

insert:
 
Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL
 
Injection
Gemcitabine Ebewe
 
SZ
MP
 
D
 
[8]     Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ with the manner of administration Injection :
omit:      
Irinotecan Kabi
PK
MP
C3184
D
 
[9]     Schedule 1 Part 1, entry for Mitozantrone in the form ‘Injection 20 mg (as hydrochloride) in 10 mL’ with the manner of administration Injection :
omit:      
Pfizer Australia Pty Ltd
PF
MP
 
D
 
[10]  Schedule 1 Part 1, entry for Oxaliplatin in the form ‘Solution concentrate for I.V. infusion 50 mg in 10 mL’ with the manner of administration Injection :
omit:      
Oxaliplatin Kabi
PK
MP
C3900 C3901 C3930 C3939
D
 
[11]  Schedule 1 Part 1, entry for Paclitaxel in the form ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’ with the manner of administration Injection :
omit:      
Paclitaxel Kabi
PK
MP
C3186 C3890 C3902 C3917  C3955 C3956
 
D
[12]  Schedule 1 Part 1, entry for Paclitaxel in the forms ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’; ‘Solution concentrate for I.V. infusion 30 mg in 5 mL’ and ‘Solution concentrate for I.V. infusion 300 mg in 50 mL’ with the manner of administration Injection :
omit:      
 
Taxol
BQ
MP
C3186 C3890 C3902 C3917  C3955 C3956
D
 
Read Entire Law on www.comlaw.gov.au